Unknown

Dataset Information

0

Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.


ABSTRACT: Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are severe disease manifestations that can occur following sequential infection with different dengue virus serotypes (DENV1-4). At present, there are no licensed therapies to treat DENV-induced disease. DHF and DSS are thought to be mediated by serotype cross-reactive antibodies that facilitate antibody-dependent enhancement (ADE) by binding to viral antigens and then Fc? receptors (Fc?R) on target myeloid cells. Using genetically engineered DENV-specific antibodies, it has been shown that the interaction between the Fc portion of serotype cross-reactive antibodies and Fc?R is required to induce ADE. Additionally, it was demonstrated that these antibodies were as neutralizing as their non-modified variants, were incapable of inducing ADE, and were therapeutic following a lethal, antibody-enhanced infection. Therefore, we hypothesized that avian IgY, which do not interact with mammalian Fc?R, would provide a novel therapy for DENV-induced disease. We demonstrate here that goose-derived anti-DENV2 IgY neutralized DENV2 and did not induce ADE in vitro. Anti-DENV2 IgY was also protective in vivo when administered 24 hours following a lethal DENV2 infection. We were also able to demonstrate via epitope mapping that both full-length and alternatively spliced anti-DENV2 IgY recognized different epitopes, including epitopes that have not been previously identified. These observations provide evidence for the potential therapeutic applications of goose-derived anti-DENV2 IgY.

SUBMITTER: Fink AL 

PROVIDER: S-EPMC5517069 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.

Fink Ashley L AL   Williams Katherine L KL   Harris Eva E   Alvine Travis D TD   Henderson Thomas T   Schiltz James J   Nilles Matthew L ML   Bradley David S DS  

PLoS neglected tropical diseases 20170707 7


Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are severe disease manifestations that can occur following sequential infection with different dengue virus serotypes (DENV1-4). At present, there are no licensed therapies to treat DENV-induced disease. DHF and DSS are thought to be mediated by serotype cross-reactive antibodies that facilitate antibody-dependent enhancement (ADE) by binding to viral antigens and then Fcγ receptors (FcγR) on target myeloid cells. Using genetically e  ...[more]

Similar Datasets

| S-EPMC6466411 | biostudies-literature
| S-EPMC7157666 | biostudies-literature
| S-EPMC7157777 | biostudies-literature
| S-EPMC6062107 | biostudies-literature
| S-EPMC5763606 | biostudies-literature
| S-EPMC3715404 | biostudies-literature
| S-EPMC6789886 | biostudies-literature
| S-EPMC8757693 | biostudies-literature
| S-EPMC2820409 | biostudies-literature
| S-EPMC2643768 | biostudies-literature